Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dyadic Focuses On Pharma Sector | Contract Pharma

What are you searching for?

Sign in
Breaking News

Dyadic Focuses On Pharma Sector

Sells industrial technology business to DuPont Industrial Biosciences for $75 million

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dyadic International Inc. is selling its industrial technology business to DuPont’s Industrial Biosciences business for $75 million. Dyadic says it intends to focus exclusively on its biopharmaceutical business.

“This transaction is an exceptional opportunity to unlock value and provide Dyadic operational flexibility to further develop our pharmaceutical business,” said Mark Emalfarb, founder and chief executive officer, Dyadic. “We will now focus our C1 technology exclusively on the pharmaceutical sector where we believe it has the potential to help develop and manufacture drugs and vaccines faster and more efficiently than existing production systems.”

Dyadic will sell to DuPont all of its enzyme and technology assets, including its C1 platform, a technology for producing enzyme products used in a broad range of industries. DuPont has granted back to Dyadic co-exclusive rights to the C1 technology for use in human and animal pharmaceutical applications, with exclusive ability to enter into sub-license agreements in that field.  DuPont will retain certain rights to utilize the C1 technology for development and production of pharmaceutical products, for which it will make royalty payments to Dyadic upon commercialization.   

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics